Aclaris says FDA grants Fast Track status for modzatinib in moderate to severe lichen planus

PUBT · 2d ago
Aclaris says FDA grants Fast Track status for modzatinib in moderate to severe lichen planus
  • Aclaris Therapeutics received FDA Fast Track designation for modzatinib (ATI-2138) in moderate to severe lichen planus.
  • The designation supports an expedited development and review path, including potential rolling NDA submission.
  • A phased, multi-part Phase 2b trial is expected to start in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.